INVESTOR
Advancing Regenerative Medicine and Accelerating Therapeutic Discovery
We detailed three research projects in regenerative medicine with potential for commercialization within five to ten years: on human brain models, a method to stimulate production of ultra-powerful immune cells at scale, and mitochondrial enhancement therapy.
The Opportunity
Induced pluripotent stem cells (iPSCs), derived from blood cells, have made it possible to imagine a world of novel therapeutic modalities as well as scientific discoveries. For an interested individual investor, we highlighted three of Mount Sinai’s most advanced projects leveraging iPSCs—distilling highly technical science, describing the market opportunity, and defining a commercialization plan for each.
The Process
This proposal gave science writing a chance to shine. Interviews with the principal investigator of each project informed our work to capture the intricacies of the science that made it so compelling—while also clearly outlining the path these advancements can take to transform research, adoptive cell therapies, and aging.
